Item 8.01 Other Events.

On May 14, 2021, Ultragenyx Pharmaceutical Inc. (the "Company") issued a press release (the "Press Release") announcing positive multi-year durability data from its ongoing Phase 1/2 gene therapy studies and data on the Company's HeLa 3.0 manufacturing platform presented at the American Society of Gene & Cell Therapy 2021 Annual Meeting. A copy of the Press Release is filed as Exhibit 99.1

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit No. Description

99.1          Press Release, dated May 14, 2021.
104         The cover page from the Company's Current Report on Form 8-K dated May
            14, 2021 formatted in Inline XBRL.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses